DrugPatentWatch Database Preview
Drugs in Development Information for abraxane
What is the development status for investigational drug abraxane?
abraxane is an investigational drug.
There have been 370 clinical trials for abraxane.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 12th 2018.
The most common disease conditions in clinical trials are Pancreatic Neoplasms, Breast Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Celgene Corporation, National Cancer Institute (NCI), and Celgene.
There is one US patent protecting this investigational drug and fourteen international patents.
Summary for abraxane
| US Patents | 1,103 |
| International Patents | 14,864 |
| US Patent Applications | 8,625 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 199 |
| Clinical Trial Progress | Phase 3 (2018-03-12) |
| Vendors | 58 |
Recent Clinical Trials for abraxane
| Title | Sponsor | Phase |
|---|---|---|
| Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer | Lexicon Pharmaceuticals | Phase 2 |
| Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer | Emory University | Phase 2 |
| Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A) | Merck Sharp & Dohme Corp. | Phase 2 |
Clinical Trial Summary for abraxane
Top disease conditions for abraxane
Top clinical trial sponsors for abraxane
US Patents for abraxane
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| abraxane | Start Trial | Pyrazol-3-ones that activate pro-apoptotic BAX | Dana-Farber Cancer Institute, Inc. (Boston, MA) | Start Trial |
| abraxane | Start Trial | Compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| abraxane | Start Trial | 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors | Vernalis (R&D) Limited (Winnersh, GB) | Start Trial |
| abraxane | Start Trial | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof | Dana-Farber Cancer Institute, Inc. (Boston, MA) Beth Israel Deaconess Medical Center, Inc. (Boston, MA) | Start Trial |
| abraxane | Start Trial | Anti-cancer agents and preparation thereof | Purdue Research Foundation (West Lafayette, IN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for abraxane
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| abraxane | Australia | 2012322660 | 2031-10-11 | Start Trial |
| abraxane | Australia | 2017228527 | 2031-10-11 | Start Trial |
| abraxane | Canada | 2851788 | 2031-10-11 | Start Trial |
| abraxane | European Patent Office | 2766355 | 2031-10-11 | Start Trial |
| abraxane | World Intellectual Property Organization (WIPO) | 2013055949 | 2031-10-11 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
